Title: Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
Abstract: Final results from the randomised phase III METEOR study have been recently published and confirmed the superiority of cabozantinib over everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma (mRCC) who received at least one previous VEGFR tyrosine-kinase inhibitor (TKI) (1).